Max Kates

1.7K posts

Max Kates banner
Max Kates

Max Kates

@MaxKates

Associate Professor of Urology and Oncology Director, Division of Urologic Oncology @bradyurology

Katılım Mayıs 2014
420 Takip Edilen2.1K Takipçiler
Max Kates
Max Kates@MaxKates·
NCCN Guidelines for HR-NMIBC show cystectomy as preferred over BCG for those with very high risk features (defined as prostatic urethra, LVI,histologic variants).I can understand RC for variants/widespreaad prostatic urethra, but LVI? Anyone use LVI as basis for recommending RC?
English
4
1
15
3.3K
Max Kates
Max Kates@MaxKates·
Please circulate among your fellows and junior faculty... urologists, medoncs, radoncs, basic and translational scientists... John Quale Travel Fellowships: bcan.org/bcan-research/…
English
0
10
19
3.5K
Max Kates retweetledi
Urologic Oncology
Urologic Oncology@UrolOncol·
🔥@UrolOncol March issue! 💡Highlights 1⃣Alopecia is an underreported AE of intravesical gemcitabine 2⃣Time to alopecia: <1 wk to >4 wks 3⃣65% experienced severe alopecia 4⃣All were temporary and resolved spontaneously Free access link: bit.ly/4sj7te7
Urologic Oncology tweet media
English
1
5
18
8.4K
Max Kates
Max Kates@MaxKates·
@DrSpratticus @UroDocAsh I agree with this. Makes no sense for anyone other than a urologist to manage urologic issues. IMO it's a passive aggressive conversation by urologists who view RT complications as underreported or underappreciated (I disagree btw). But obviously uros should manage.
English
2
2
17
3.5K
Daniel E Spratt
Daniel E Spratt@DrSpratticus·
It is interesting to me that people went into the field of urology to help with urological problems (thank you!)…but a vocal minority seem frustrated they need to manage urological problems. I can’t speak for anyone but myself but I am betting your radoncs at MDACC are thankful for you taking care of patients with urological issues, no matter the cause! When a patient has an MI or stroke during or after surgery I assume you refer them to specialists to help. We all can manage things within reason. I appreciate you 😁
English
3
1
22
2K
Ashish M. Kamat, MD, MBBS
Ashish M. Kamat, MD, MBBS@UroDocAsh·
As in prior years, we will again run a series of live polls tied to the Rapid Fire Debate session at #EAU26. There are no right answers; only your honest perspective. Your vote and comments will help drive the discussion, during the new “Presidential Debate” format introduced by @MaartenAlbersen #UroTwitter #BladderCancer #EAU26 #GU26
Ashish M. Kamat, MD, MBBS@UroDocAsh

As we wrap a whirlwind of data in bladder cancer at #GU26, wishing everyone safe travels home. Rest up - London and #EAU26 are just around the corner! I'm especially excited to once again lead the "Common Problems and Controversies in Bladder Cancer: Rapid-fire Debates." Friday 13 March 10:45 - 12:15 We’ve designed this session to cut through the noise - no long lectures - just leading experts, opposing viewpoints, and the direct clinical insights you need for daily practice. It remains one of the most anticipated highlights of the meeting for a reason!

English
2
6
24
8.3K
Max Kates retweetledi
Armine Smith
Armine Smith@akfsurgeon·
At #GU26 on female cancer disparities. Grateful to be joined by an outstanding group of colleagues with stimulating insights. Surgical quality and structured survivorship must be central to how we define excellence. #GU26 #BladderCancer #WomensHealth
Andrea Apolo, M.D.@apolo_andrea

Definitive radiation and surgery can be tailored for women safely in a comprehensive approach and trials are ongoing. Great overviews by Dr. Xinglei Shen, and Dr. Armine Smith @akfsurgeon @ASCO #GU26

English
0
3
8
1.2K
Max Kates
Max Kates@MaxKates·
Realizing EFS differences are not statistically significant, its hard to ignore that Tokyo looks slightly better & has higher G3+ AEs. This goes along with what we see in practice--patients with BCG symptoms often have good outcomes...@UroDocAsh @siadaneshmand @eugene_pietzak
Andrea Apolo, M.D.@apolo_andrea

@SvatekRob presents the ⭐️ SUPER important LBA629 SWOG1602 Phase3 study of different BCG stains plus BCG intradermal priming in NMIBC showing that a different BCG Tokyo 172 was not inferior to TICE. Priming did not improve recurrence @ASCO #GU26 #BladderCancer

English
0
1
9
1.2K
Max Kates retweetledi
Trushar Patel
Trushar Patel@TrusharPatelMD·
@MaxKates 💯Important point . In Florida, we’re actively working on initiatives to extend this evidence beyond major academic and population centers—bringing education and care pathways to community and rural settings. Bridging the data-to-practice divide is the next challenge.
Tampa, FL 🇺🇸 English
0
1
2
220
Max Kates
Max Kates@MaxKates·
This is a nice study demonstrating that active surveillance for LgTa is safe from a patients reported QOL and mental health metric #GU26. In appropriately selected patients AS is a great option. asco.org/abstracts-pres…
English
0
2
4
516
Max Kates
Max Kates@MaxKates·
Neoadjuvant EVP vs CisGem Now Out and WOW. #GU26 Path CR Rate Difference of 55.8% vs 32.5% is mind boggling, obviously leading to differences in EFS and OS... asco.org/abstracts-pres…
English
0
15
61
6.2K
Max Kates
Max Kates@MaxKates·
We will see the presentation later this AM but right off the bat this strikes me as a higher risk cohort compared to CREST/ALBAN/POTOMAC.
Max Kates@MaxKates

Big News from #GU26: S1602 Topline: Tokyo Strain BCG Non-Inferior to Tice Strain.But increased G3-4 AEs with Tokyo.Intradermal Priming did not help.Huge Congrats to the study investigators on this trial which will hopefully get more BCG into the US market.asco.org/abstracts-pres…

English
0
0
3
770
Max Kates
Max Kates@MaxKates·
Big News from #GU26: S1602 Topline: Tokyo Strain BCG Non-Inferior to Tice Strain.But increased G3-4 AEs with Tokyo.Intradermal Priming did not help.Huge Congrats to the study investigators on this trial which will hopefully get more BCG into the US market.asco.org/abstracts-pres…
Max Kates tweet media
English
0
4
16
2.3K
Max Kates
Max Kates@MaxKates·
With EV-303 & EV-304 data, the challenge shifts to making up-front therapy the universal standard for MIBC. This #GU26 study suggests it won't happen overnight—real-world adoption often lags behind trial success. 🔗 Data: asco.org/abstracts-pres…
English
1
0
8
876
Max Kates
Max Kates@MaxKates·
Why is this Important? With EV 303 Data demonstrating 60%+ CRs with neoadjuvant EVP, we need to be confident in understanding who needs surgical consolidation and who may not....asco.org/abstracts-pres…
Max Kates tweet media
Max Kates@MaxKates

Can we accurately stage cCRs in MIBC? JH & Fox Chase studies show the challenge. The future? #GUASCO Niagara data shows utDNA + ctDNA may accurately confer cCRs & prognosis. 🔗 Niagara: asco.org/abstracts-pres… 🔗 JH: europeanurology.com/article/S0302-…🔗 Fox Chase: auajournals.org/doi/abs/10.109…

English
0
1
13
1.7K
Max Kates
Max Kates@MaxKates·
Don’t let this #GUASCO "negative study" fly under the radar 🔹 518 patient RCT in MIBC for Bladder-sparing TAR-200+IO vs Chemorads 🔹 2yr Bladder-intact EFS: ~58 vs 66% (NS) 🔹 OS: ~84% both arms This data matters for future of organ preservation asco.org/abstracts-pres…
English
0
9
32
3.3K

Keşfet

@arkhaki @BladderCancerUS @ERPlimackMD @shilpaonc @UroDocAsh @FaltasLab @m_e_nielsen @WilliamKimMD